Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea

Abstract Background Anti-PD1 inhibitors have been approved for the treatment of recurrent or metastatic head and neck cancer (HNC), as a result of Global Phase III trials. However, the clinical outcomes of immune checkpoint inhibitors in patients who are not eligible for clinical trials or have vari...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hyera Kim, Minsuk Kwon, Binnari Kim, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Keunchil Park, Myung-Ju Ahn
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2020-08-01
coleção:	BMC Cancer
Assuntos:	Immune checkpoint inhibitor Head and neck cancer Pembrolizumab Nivolumab
Acesso em linha:	http://link.springer.com/article/10.1186/s12885-020-07214-4
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!